Pembrolizumab Continuation With Additional Chemotherapy After Progression With PD-1/PD-L1 Inhibitor Monotherapy in Patients With Advanced NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study
Clin. Cancer Res 2022 Jun 01;28(11)2321-2328, HA Jung, S Park, YL Choi, SH Lee, JS Ahn, MJ Ahn, JM SunFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.